Form: 424B3

Prospectus filed pursuant to Rule 424(b)(3)

May 11, 2022

 

Filed pursuant to Rule 424(b)(3) 
Registration Statement No. 333-258748

 

Prospectus Supplement No. 1

(To Prospectus dated April 27, 2022)

 

This prospectus supplement updates, amends and supplements the prospectus dated April 27, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-258748). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.

 

This prospectus supplement is being filed to update, amend and supplement the information included in the Prospectus with information on Evolv Technologies Holdings, Inc.’s unaudited first quarter 2022 financial results, which is set forth below.

 

This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.

 

Our Class A common stock is quoted on The Nasdaq Stock Market, or NASDAQ, under the symbol “EVLV” and our warrants are quoted on the NASDAQ under the symbol “EVLVW.” On May 11, 2022, as reported on NASDAQ, the closing sale price of our Class A common stock was $1.77 and the closing sale price of our warrants was $0.26.

 

We are an “emerging growth company” under federal securities laws and are subject to reduced public company reporting requirements. Investing in our securities involves certain risks. See “Risk Factors” beginning on page 3 of the Prospectus.

 

Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

 

The date of this prospectus supplement is May 11, 2022.

 

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): May 11, 2022

 

Evolv Technologies Holdings, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-39417   84-4473840
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

500 Totten Pond Road, 4th Floor

Waltham, Massachusetts

  02451
(Address of principal executive offices)   (Zip Code)

 

(781) 374-8100

Registrant’s telephone number, including area code

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Class A common stock, par value $0.0001 per share   EVLV   The Nasdaq Stock Market
Warrants to purchase one share of Class A common stock   EVLVW   The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

  

On May 11, 2022, Evolv Technologies Holdings, Inc. (the “Company”) announced financial results for the three months ended March 31, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

  

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
   
99.1 Press Release, dated May 11, 2022.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

  

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Evolv Technologies Holdings, Inc.
     
Date: May 11, 2022 By: /s/ Peter George
    Name: Peter George
    Title: Chief Executive Officer

 

 

 

 

Exhibit 99.1

 

 

Investor Relations:

Brian Norris

Vice President of Investor Relations

bnorris@evolvtechnology.com

 

Evolv Technology Reports Strong First Quarter Financial Results

 

Company Reaffirms Outlook for 2022

 

· Q1 Revenue of $8.7 million, up 118% year-over-year
· Q1 Ending ARR of $16.6 million, up 207% year-over-year
· Q1 Ending Evolv Express® subscriptions of 910, up 227% year-over-year

 

Waltham, Massachusetts – May 11, 2022 – Evolv Technology (NASDAQ: EVLV), a global leader in weapons detection security screening, today announced financial results for its first quarter ended March 31, 2022 and reaffirmed its business outlook for 2022.

 

“We’re pleased to report solid first quarter results which were highlighted by strong growth in revenues, new customers and Evolv Express subscribers,” said Peter George, President and Chief Executive Officer of Evolv Technology. “Our results continue to reflect our expanding leadership position in North America as more facility operators adopt our solutions to digitally transform their security operations. Looking ahead, we believe we remain well positioned to execute on our strategic growth plans.”

 

Results for the First Quarter of 2022

 

Total revenue for the first quarter of 2022 was $8.7 million, an increase of 118% compared to $4.0 million for the first quarter of 2021. Total Contract Value (“TCV”)1 of orders booked for the first quarter of 2022 was $19.2 million, an increase of 128% compared to $8.4 million in the first quarter of 2021. Annual Recurring Revenue (“ARR”)2 was $16.6 million at the end of first quarter of 2022, an increase of 207% compared to $5.4 million in the first quarter of 2021. Net loss for the first quarter of 2022 was ($14.6) million, or ($0.10) per basic and diluted share, compared to net loss of ($13.8) million, or ($1.32) per basic and diluted share, for the first quarter of 2021. Adjusted earnings (loss)3 for the first quarter of 2022 was ($19.1) million, or ($0.13) per basic and diluted share, compared to ($10.5) million, or ($1.01) per basic and diluted share, for the first quarter of 2021. Adjusted EBITDA3 for the first quarter of 2022 was ($18.2) million, compared to ($7.6) million for the first quarter of 2021. As of March 31, 2022, the Company had cash and cash equivalents of $270.9 million compared to $307.5 million as of December 31, 2021.

 

 

 

Company Reaffirms Outlook for 2022

 

The Company today commented on its business outlook for 2022. The Company's outlook is based on the current indications for its business, which may change at any time.

 

    2022 Business Outlook
Estimate (In millions)   Issued March 14, 2022   Issued May 11, 2022
Total Revenue   $29-$31   No change
Annual Recurring Revenue2 (ARR) at 12/31   $27-$28   No change
Adjusted EBITDA3   ($65-$67)   No change
Cash and Cash Equivalents   $220-$230   No change

 

Company to Host Live Conference Call and Webcast

 

The Company’s management team plans to host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss the financial results as well as management’s outlook for the business and other matters. The conference call may be accessed in the United States by dialing +1.877.692.8955 and using access code 774298. The conference call may be accessed outside of the United States by dialing +1.234.720.6979 and using the same access code. The conference call will be simultaneously webcast on the Company’s investor relations website, which can be accessed at http://ir.evolvtechnology.com. A replay of the conference call will be available for a period of 30 days by dialing +1.866.207.1041 or +1.402.970.0847 and using access code 5434851 or by accessing the webcast replay on the Company’s investor relations website at http://ir.evolvtechnology.com.

 

About Evolv Technology

 

Evolv Technology (NASDAQ: EVLV) is a global leader in weapons detection security screening. Our mission is Evolv Technology (NASDAQ: EVLV) is a leader in weapons detection for security screening, securing the world’s most iconic venues and companies. Its mission is enabling a better experience and better security for venues, creating a safer world to work, learn, and play by transforming physical security to make everywhere safer. It gives sports fans, theme park visitors, concertgoers, shoppers, employees, students, and others peace of mind so that they can gather without fear of violence. Its security screening has scanned more than 250 million people, second only to the Department of Homeland Security’s Transportation Security Administration (TSA) in the United States, and its technology combines powerful, advanced sensors with proven artificial intelligence (AI), security ecosystem integrations, and comprehensive venue analytics to reliably detect threats 10 times faster than traditional metal detectors. Evolv Technology, Evolv Express®, Evolv Insights™, and Evolv Cortex AI™ are registered trademarks or trademarks of Evolv Technologies, Inc. in the United States and other jurisdictions. For more information, visit https://evolvtechnology.com.

 

1 We define Total Contract Value, or TCV, of orders booked as the total value of the contract over the specified term. Our calculation of TCV is not adjusted for the impact of any known or projected future events (such as customer cancellations, upgrades or downgrades, or price increases or decreases). TCV should be viewed independently of, and not as a substitute for or forecast of, revenue and deferred revenue. Our calculation of TCV may differ from similarly titled metrics presented by other companies.

 

2 We define Annual Recurring Revenue, or ARR, as subscription revenue and the recurring service revenue related to purchase subscriptions for the final month of the quarter normalized to a one-year period. Our calculation of ARR is not adjusted for the impact of any known or projected future events (such as customer cancellations, upgrades or downgrades, or price increases or decreases) that may cause any such contract not to be renewed on its existing terms. In addition, the amount of actual revenue that we recognize over any 12-month period is likely to differ from ARR at the beginning of that period, sometimes significantly. This may occur due to new bookings, cancellations, upgrades, downgrades or other changes in pending renewals, as well as the effects of professional services revenue and acquisitions or divestitures. As a result, ARR should be viewed independently of, and not as a substitute for or forecast of, revenue and deferred revenue. Our calculation of ARR may differ from similarly titled metrics presented by other companies.

 

3 Non-GAAP Financial Measures In this press release, the Company’s adjusted gross profit, adjusted gross margin, adjusted EBITDA and adjusted earnings (loss) are not presented in accordance with generally accepted accounting principles (GAAP) and are not intended to be used in lieu of GAAP presentations of results of operations. Adjusted gross profit and adjusted gross margin exclude one-time items which management believes provides a more meaningful representation of contribution margin. Adjusted EBITDA is defined as net income (loss) plus depreciation and amortization, share-based compensation, and certain other one-time expenses. Adjusted earnings (loss) is defined as net income (loss) plus stock-based compensation, change in fair value of derivative liability, change in fair value of contingent earn-out liability, change in fair value of contingently issuable common stock liability, change in fair value of public warrant liability, change in fair value of common stock warrant liability, restructuring expenses, loss on impairment of lease equipment, and certain other one-time expenses. Management presents non-GAAP financial measures because it considers them to be important supplemental measures of performance. Management uses non-GAAP financial measures for planning purposes, including analysis of the Company's performance against prior periods, the preparation of operating budgets and to determine appropriate levels of operating and capital investments. Management also believes non-GAAP financial measures provide additional insight for analysts and investors in evaluating the Company's financial and operational performance. However, non-GAAP financial measures have limitations as an analytical tool and are not intended to be an alternative to financial measures prepared in accordance with GAAP. We intend to provide non-GAAP financial measures as part of our future earnings discussions and, therefore, the inclusion of non-GAAP financial measures will provide consistency in our financial reporting. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of our non-GAAP financial measures to their most directly comparable GAAP measures has been provided in this press release.

 

 

 

Forward-Looking Statements

 

Certain statements in this press release may constitute “forward-looking” statements and information, within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 that relate to our current expectations and views of future events including but not limited to statements regarding our ability to meet our business outlook for revenue and profitability. Forward-looking statements involve the Company’s current expectations and projections relating to its financial condition, competitive position, future financial results, plans, objectives, and business. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, these forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “should,” “could,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or the negative of these terms or other similar expressions. These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect the Company’s current views with respect to future events and the Company’s performance and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation expectations regarding the Company’s strategies and future financial performance, including its future business plans or objectives, prospective performance and opportunities and competitors, revenues, products and services, pricing, operating expenses, market trends, liquidity, cash flows and uses of cash, capital expenditures; the Company’s history of losses and lack of profitability; the Company’s reliance on third party contract manufacturing; the rate of innovation required to maintain competitiveness in the markets in which the Company competes; the competitiveness of the market in which the Company competes; the ability for the Company to obtain, maintain, protect and enforce the Company’s intellectual property rights; the concentration of the Company’s revenues on a single solution; the Company’s ability to timely design, produce and launch its solutions, the Company’s ability to invest in growth initiatives and pursue acquisition opportunities; the limited liquidity and trading of the Company’s securities; geopolitical risk and changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; operational risk; risk that the COVID-19 pandemic, including variants, vaccine roll-out efforts, and local, state, and federal responses to addressing the pandemic may have an adverse effect on the Company’s business operations, as well as the Company’s financial condition and results of operations; litigation and regulatory enforcement risks, including the diversion of management time and attention and the additional costs and demands on resources; and the risk factors set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission on March 28, 2022.

 

These statements reflect management’s current expectations regarding future events and operating performance and speak only as of the date of this press release. You should not put undue reliance on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

 

 

 

Evolv Technology

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share data)

(Unaudited)

 

    Three Months Ended
March 31,
 
    2022     2021  
Revenue:                
Product revenue   $ 5,194     $ 2,502  
Subscription revenue     3,020       1,300  
Service revenue     501       197  
Total revenue     8,715       3,999  
                 
Cost of revenue:                
Cost of product revenue     5,576       2,229  
Cost of subscription revenue     1,065       595  
Cost of service revenue     448       127  
Total cost of revenue     7,089       2,951  
Gross profit     1,626       1,048  
                 
Operating expenses:                
Research and development     4,286       3,612  
Sales and marketing     12,053       3,684  
General and administrative     11,093       2,899  
Loss from impairment of property and equipment     96       -  
Total operating expenses     27,528       10,195  
Loss from operations     (25,902 )     (9,147 )
                 
Interest expense     (142 )     (2,447 )
Interest income     209       -  
Change in fair value of derivative liability           (1,425 )
Change in fair value of contingent earn-out liability     4,226       -  
Change in fair value of contingently issuable common stock liability     1,472       -  
Change in fair value of public warrant liability     5,586       -  
Change in fair value of common stock warrant liability           (736 )
Total other income (expense)   $ 11,351     $ (4,608 )
                 
Net loss and comprehensive loss – basic and diluted   $ (14,551 )   $ (13,755 )
                 
Net loss per share – basic and diluted   $ (0.10 )   $ (1.32 )
                 
Weighted average common shares outstanding – basic and diluted     142,878,406       10,443,323  

 

 

 

Evolv Technology

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

(Unaudited)

 

    March 31,
2022
    December 31,
2021
 
Assets                
Current assets:                
Cash and cash equivalents   $ 270,872     $ 307,492  
Restricted cash     400       400  
Accounts receivable, net     8,589       6,477  
Inventory     7,181       5,140  
Current portion of contract assets     1,448       1,459  
Current portion of commission asset     1,477       1,645  
Prepaid expenses and other current assets     17,252       11,047  
Total current assets     307,219       333,660  
Restricted cash, noncurrent     275       275  
Contract assets, noncurrent     3,321       3,418  
Commission asset, noncurrent     4,239       3,719  
Property and equipment, net     25,282       21,592  
Operating lease right-of-use assets     2,287       -  
Other assets     1,275       401  
Total assets   $ 343,898     $ 363,065  
                 
Liabilities and Stockholders’ Equity                
Current liabilities:                
Accounts payable   $ 4,645     $ 6,363  
Accrued expenses and other current liabilities     7,118       9,183  
Current portion of deferred revenue     7,433       6,690  
Current portion of deferred rent           135  
Current portion of long-term debt     3,000       2,000  
Current portion of operating lease liabilities     1,089        
Total current liabilities     23,285       24,371  
Deferred revenue, noncurrent     4,517       2,475  
Deferred rent, noncurrent           333  
Long-term debt, noncurrent     6,950       7,945  
Operating lease liabilities, noncurrent     1,634        
Contingent earn-out liability     18,128       20,809  
Contingently issuable common stock liability     3,792       5,264  
Public warrant liability     5,444       11,030  
Total liabilities     63,750       72,227  
                 
Stockholders’ Equity:                
Preferred stock     -       -  
Common stock     14       14  
Additional paid-in capital     399,424       395,563  
Accumulated deficit     (119,290 )     (104,739 )
Total stockholders’ equity     280,148       290,838  
Total liabilities and stockholders’ equity   $ 343,898     $ 363,065  

 

 

 

EVOlv TECHNOLOGY

Consolidated Statements Of Cash Flows

(In thousands)

(Unaudited)

 

    Three Months Ended
March 31,
 
    2022     2021  
Cash flows from operating activities:                
Net loss   $ (14,551 )   $ (13,755 )
Adjustments to reconcile net income to net cash provided by operating activities:                
Depreciation and amortization     948       452  
Write off of inventory     324        
Adjustment to property and equipment for sales type leases     (321 )      
Loss from impairment of property and equipment     96        
Stock-based compensation     5,190       1,082  
Noncash interest expense     5       2,344  
Noncash lease expense     197        
Provision recorded for allowance for doubtful accounts           (63 )
Change in fair value of derivative liability           1,425  
Change in fair value of common stock warrant liability           736  
Change in fair value of earn-out liability     (4,226 )      
Change in fair value of contingently issuable common stock     (1,472 )      
Change in fair value of public warrant liability     (5,586 )      
Changes in operating assets and liabilities                
Accounts receivable     (2,112 )     (874 )
Inventory     (6,985 )     (433 )
Commission assets     (351 )     (391 )
Contract assets     108       (119 )
Prepaid expenses and other current assets     (5,280 )     (4,104 )
Accounts payable     (1,867 )     1,194  
Deferred revenue     2,778       (621 )
Deferred rent     (468 )     (11 )
Accrued expenses and other current liabilities     (2,065 )     1,100  
Operating lease liabilities     (229 )      
Net cash used in operating activities     (35,867 )     (12,038 )
                 
Cash flows from investing activities:                
Development of internal-use software     (646 )     -  
Purchases of property and equipment     (323 )     (2,522 )
Net cash used in investing activities     (969 )     (2,522 )
                 
Cash flows from financing activities:                
Proceeds from exercise of stock options     216       455  
Repayment of financing obligations     -       (359 )
Proceeds from long-term debt, net of issuance costs     -       31,882  
Net cash provided by financing activities     216       31,978  
                 
Net increase (decrease) in Cash, cash equivalents and restricted cash     (36,620 )     17,418  
                 
Cash, cash equivalents and restricted cash, beginning of period     308,167       4,704  
Cash, cash equivalents and restricted cash, end of period   $ 271,547     $ 22,122  

 

 

 

EVOlv TECHNOLOGY

Reconciliation of FORECASTED 2022 NET Loss to Adjusted EBITDA

(In thousands)

(Unaudited)

 

    Twelve Months Ended
December 31, 2022
 
    High     Low  
Net income (loss)   $ (83,000 )   $ (85,000 )
Adjustments to reconcile net income (loss) to Adjusted EBITDA:                
Depreciation and amortization     6,000       6,000  
Stock-based compensation     11,000       11,000  
Other expense     1,000       1,000  
Adjusted EBITDA   $ (65,000 )   $ (67,000 )

 

EVOlv TECHNOLOGY

SuMMARY OF KEY OPERATING STATISTICS

(Unaudited)

 

($ in thousands)   December 31,
2020
    March 31,
2021
    June 30,
2021
    September 30,
2021
    December 31,
2021
    March 31,
2022
 
New customers     6       13       21       23       27       44  
Total contract value of orders booked   $ 5,956     $ 8,424     $ 10,476     $ 16,995     $ 17,916     $ 19,167  
Annual recurring revenue   $ 4,034     $ 5,424     $ 7,423     $ 9,932     $ 12,907     $ 16,641  
Remaining performance obligation   $ 13,381     $ 17,658     $ 24,930     $ 34,152     $ 40,160     $ 50,537  
Contract value for units in backlog     n/a       n/a       n/a       n/a     $ 11,270     $ 13,213  
Net additions     32       64       113       176       136       207  
Ending deployed units     214       278       391       567       703       910  

 

 

 

EVOlv TECHNOLOGY

Reconciliation of GAAP to ADJSUTED Gross profit and GAAP operating income TO ADJUSTED OPERATING INCOME

(In thousands)

(Unaudited)

 

    Three Months Ended
March 31,
 
    2022     2021  
Revenue   $ 8,715     $ 3,999  
Cost of revenue     7,089       2,951  
Gross Profit     1,626       1,048  
Stock-based compensation     60       5  
Adjusted Gross Profit   $ 1,686     $ 1,053  
                 
Gross Margin %     18.7 %     26.2 %
Adjusted Gross Margin %     19.3 %     26.3 %

 

    Three Months Ended
March 31,
 
    2022     2021  
Operating income (loss) GAAP   $ (25,902 )   $ (9,147 )
Stock-based compensation     5,190       1,082  
Restructuring expenses     324       -  
Loss on impairment of lease equipment     96       -  
Other one-time expenses     1,107       -  
Adjusted Operating Income (loss)   $ (19,185 )   $ (8,065 )

 

 

 

EVOlv TECHNOLOGY

Reconciliation of GAAP NEt income to adjusted EBITDA

(In thousands)

(Unaudited)

 

    Three Months Ended
March 31,
 
    2022     2021  
Net income (loss)   $ (14,551 )   $ (13,755 )
Depreciation & Amortization     948       452  
Stock-based compensation     5,190       1,082  
Interest and other income (expense)     (67 )     2,447  
Loss on disposal of property & equipment     -       -  
Loss on extinguishment of debt     -       -  
Change in fair value of derivative liability     -       1,425  
Change in fair value of contingent earn-out liability     (4,226 )     -  
Change in fair value of contingently issuable common stock liability     (1,472 )     -  
Change in fair value of public warrant liability     (5,586 )     -  
Change in fair value of common stock warrant liability     -       736  
Restructuring expenses     324       -  
Loss on impairment of lease equipment     96       -  
Other one-time expenses     1,107       -  
Adjusted EBITDA   $ (18,237 )   $ (7,613 )

 

EVOlv TECHNOLOGY

Reconciliation of GAAP NEt income and earnings per share to ADJUSTED EARNINGS AND earnings per share

(In thousands, except share and per share data)

(Unaudited)

 

    Three Months Ended
March 31,
 
    2022     2021  
Net income (loss)   $ (14,551 )   $ (13,755 )
Stock-based compensation     5,190       1,082  
Change in fair value of derivative liability     -       1,425  
Change in fair value of contingent earn-out liability     (4,226 )     -  
Change in fair value of contingently issuable common stock liability     (1,472 )     -  
Change in fair value of public warrant liability     (5,586 )     -  
Change in fair value of common stock warrant liability     -       736  
Restructuring expenses     324       -  
Loss on impairment of lease equipment     96       -  
Other one-time expenses     1,107       -  
Adjusted earnings (loss)   $ (19,118 )   $ (10,512 )
                 
Weighted average common shares outstanding – basic and diluted     142,878,406       10,443,323  
                 
Adjusted EPS   $ (0.13 )   $ (1.01 )

 

# # #